|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Breuer EK and Murph MM: The role of
proteomics in the diagnosis and treatment of women's cancers:
current trends in technology and future opportunities. Int J
Proteomics. 2011:3735842011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doench JG and Sharp PA: Specificity of
microRNA target selection in translational repression. Genes Dev.
18:504–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meyer SU, Thirion C, Polesskaya A,
Bauersachs S, Kaiser S, Krause S and Pfaffl MW: TNF-α and IGF1
modify the microRNA signature in skeletal muscle cell
differentiation. Cell Commun Signal. 13:42015. View Article : Google Scholar
|
|
7
|
Tian L, Fang YX, Xue JL and Chen JZ: Four
microRNAs promote prostate cell proliferation with regulation of
PTEN and its downstream signals in vitro. PLoS One. 8:e758852013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar
|
|
11
|
Nassirpour R, Mehta PP, Baxi SM and Yin
MJ: miR-221 promotes tumorigenesis in human triple negative breast
cancer cells. PLoS One. 8:e621702013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stinson S, Lackner MR, Adai AT, Yu N, Kim
HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, et
al: TRPS1 targeting by miR-221/222 promotes the
epithelial-to-mesenchymal transition in breast cancer. Sci Signal.
4:ra412011.PubMed/NCBI
|
|
13
|
Rong M, Chen G and Dang Y: Increased
miR-221 expression in hepatocellular carcinoma tissues and its role
in enhancing cell growth and inhibiting apoptosis in vitro. BMC
Cancer. 13:212013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamashita R, Sato M, Kakumu T, Hase T,
Yogo N, Maruyama E, Sekido Y, Kondo M and Hasegawa Y: Growth
inhibitory effects of miR-221 and miR-222 in non-small cell lung
cancer cells. Cancer Med. 4:551–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adams BD, Kasinski AL and Slack FJ:
Aberrant regulation and function of microRNAs in cancer. Curr Biol.
24:R762–R776. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berindan-Neagoe I, Monroig PC, Pasculli B
and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis
and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hauser B, Zhao Y, Pang X, Ling Z, Myers E,
Wang P, Califano J and Gu X: Functions of MiRNA-128 on the
regulation of head and neck squamous cell carcinoma growth and
apoptosis. PLoS One. 10:e01163212015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Visone R, Russo L, Pallante P, De Martino
I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, et
al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human
thyroid papillary carcinomas, regulate p27Kip1 protein
levels and cell cycle. Endocr Relat Cancer. 14:791–798. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fornari F, Gramantieri L, Ferracin M,
Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM,
Bolondi L, et al: MiR-221 controls CDKN1C/p57 and CDKN1B/p27
expression in human hepatocellular carcinoma. Oncogene.
27:5651–5661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Medina R, Zaidi SK, Liu CG, Stein JL, van
Wijnen AJ, Croce CM and Stein GS: MicroRNAs 221 and 222 bypass
quiescence and compromise cell survival. Cancer Res. 68:2773–2780.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O'Hara AJ, Wang L, Dezube BJ, Harrington
WJ Jr, Damania B and Dittmer DPP: Tumor suppressor microRNAs are
underrepresented in primary effusion lymphoma and Kaposi sarcoma.
Blood. 113:5938–5941. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Okamoto K, Miyoshi K and Murawaki Y:
miR-29b, miR-205 and miR-221 enhance chemosensitivity to
gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One.
8:e776232013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cecconi F, Alvarez-Bolado G, Meyer BI,
Roth KA and Gruss P: Apaf1 (CED-4 homolog) regulates programmed
cell death in mammalian development. Cell. 94:727–737. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zou H, Henzel WJ, Liu X, Lutschg A and
Wang X: Apaf-1, a human protein homologous to C. elegans CED-4,
participates in cytochrome c-dependent activation of caspase-3.
Cell. 90:405–413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao Y, Liang W, Hu X, Zhang W, Stetler RA,
Vosler P, Cao G and Chen J: Neuroprotection against
hypoxic-ischemic brain injury by inhibiting the apoptotic protease
activating factor-1 pathway. Stroke. 41:166–172. 2010. View Article : Google Scholar
|
|
27
|
Yong FL, Wang CW, Roslani AC and Law CW:
The involvement of miR-23a/APAF1 regulation axis in colorectal
cancer. Int J Mol Sci. 15:11713–11729. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Zio D, Bordi M, Tino E, Lanzuolo C,
Ferraro E, Mora E, Ciccosanti F, Fimia GM, Orlando V and Cecconi F:
The DNA repair complex Ku70/86 modulates Apaf1 expression upon DNA
damage. Cell Death Differ. 18:516–527. 2011. View Article : Google Scholar :
|
|
29
|
Ho CK, Bush JA and Li G: Tissue-specific
regulation of Apaf-1 expression by p53. Oncol Rep. 10:1139–1143.
2003.PubMed/NCBI
|
|
30
|
Marsden VS, O'Connor L, O'Reilly LA, Silke
J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ,
et al: Apoptosis initiated by Bcl-2-regulated caspase activation
independently of the cytochrome c/Apaf-1/caspase-9 apoptosome.
Nature. 419:634–637. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mustika R, Budiyanto A, Nishigori C,
Ichihashi M and Ueda M: Decreased expression of Apaf-1 with
progression of melanoma. Pigment Cell Res. 18:59–62. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Paik SS, Jang KS, Song YS, Jang SH, Min
KW, Han HX, Na W, Lee KH, Choi D and Jang SJ: Reduced expression of
Apaf-1 in colorectal adenocarcinoma correlates with tumor
progression and aggressive phenotype. Ann Surg Oncol. 14:3453–3459.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zlobec I, Minoo P, Baker K, Haegert D,
Khetani K, Tornillo L, Terracciano L, Jass JR and Lugli A: Loss of
APAF-1 expression is associated with tumour progression and adverse
prognosis in colorectal cancer. Eur J Cancer. 43:1101–1107. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li NF, Broad S, Lu YJ, Yang JS, Watson R,
Hagemann T, Wilbanks G, Jacobs I, Balkwill F, Dafou D, et al: Human
ovarian surface epithelial cells immortalized with hTERT maintain
functional pRb and p53 expression. Cell Prolif. 40:780–794. 2007.
View Article : Google Scholar : PubMed/NCBI
|
